

Subscribing organizations are encouraged to copy and distribute this table of contents for non-commercial purposes

## Biochemical Society Focused Meetings

### Matrix Turnover: Mechanisms and Common Denominators

Sheffield Hallam University, U.K., 2–3 April 2007

Edited by D. Buttle (Sheffield, U.K.)

Factors controlling matrix turnover in health and disease <b>D.J. Buttle</b>	643–646
Regulation of matrix turnover: fibroblasts, forces, factors and fibrosis <b>G.J. Laurent, R.C. Chambers, M.R. Hill and R.J. McAnulty</b>	647–651
Matrix synthesis and degradation in human intervertebral disc degeneration <b>C.L. Le Maitre, A. Pockert, D.J. Buttle, A.J. Freemont and J.A. Hoyland</b>	652–655
Brain matrix: structure, turnover and necessity <b>U. Rauch</b>	656–660
TGF- $\beta$ , Smad3 and the process of progressive fibrosis <b>J. Gauldie, P. Bonniaud, P. Sime, K. Ask and M. Kolb</b>	661–664
Three-dimensional extracellular matrix culture models of EGFR signalling and drug response <b>P.A. Kenny</b>	665–668
<b>Selected oral communications</b>	
HtrA1: a novel regulator of physiological and pathological matrix mineralization? <b>A.E. Canfield, K.D. Hadfield, C.F. Rock, E.C. Wylie and F.L. Wilkinson</b>	669–671
The molecular basis of inter- $\alpha$ -inhibitor heavy chain transfer on to hyaluronan <b>C.M. Milner, W. Tongsoongnoen, M.S. Rugg and A.J. Day</b>	672–676
Influence of the extracellular matrix on the frictional properties of tissue-engineered cartilage <b>M. Plainfossé, P.V. Hatton, A. Crawford, Z.M. Jin and J. Fisher</b>	677–679
‘Rumours of my death <i>may</i> have been greatly exaggerated’: a brief review of cell death in human intervertebral disc disease and implications for cell transplantation therapy <b>W.E.B. Johnson and S. Roberts</b>	680–682
F-actin cytoskeletal organization in intervertebral disc health and disease <b>S. Li, V.C. Duance and E.J. Blain</b>	683–685
Astrocyte–leucocyte interactions and the mechanisms regulating matrix degradation in CNS tuberculosis <b>J.A. Green and J.S. Friedland</b>	686–688

Matrix metalloproteinases: useful and deleterious <b>E. Ganea, M. Trifan, A.C. Laslo, G. Putina and C. Cristescu</b>	<b>689–691</b>
Brevican and phosphacan expression and localization following transient middle cerebral artery occlusion in the rat <b>G. Haddock, A.K. Cross, S. Allan, B. Sharrack, J. Callaghan, R.A.D. Bunning, D.J. Buttle and M.N. Woodroffe</b>	<b>692–694</b>
Regulation of fibroblast migration by tenascin-C <b>A. Trebault, E.K. Chan and K.S. Midwood</b>	<b>695–697</b>
Bone marrow stromal cells promote growth and survival of prostate cancer cells <b>N.A. Cross, M. Papageorgiou and C.L. Eaton</b>	<b>698–700</b>
Cathepsin K in the bone microenvironment: link between obesity and prostate cancer? <b>I. Podgorski, B.E. Linebaugh and B.F. Sloane</b>	<b>701–703</b>
Phagocytosis of collagen by fibroblasts and invasive cancer cells is mediated by MT1-MMP <b>H. Lee, K.L. Sodek, Q. Hwang, T.J. Brown, M. Ringuelette and J. Sodek</b>	<b>704–706</b>

---


## **Family Resemblances? Ligand Binding and Activation of Family A and B G-Protein-Coupled Receptors**

GlaxoSmithKline, Stevenage, U.K., 24–25 April 2007

**Edited by D. Poyner (Aston, U.K.) and M. Wheatley (Birmingham, U.K.)**

---

Family Resemblances? Ligand Binding and Activation of Family A and B G-Protein-Coupled Receptors <b>D.R. Poyner and M. Wheatley</b>	<b>707–708</b>
Structural basis of natural ligand binding and activation of the Class II G-protein-coupled secretin receptor <b>L.J. Miller, M. Dong, K.G. Harikumar and F. Gao</b>	<b>709–712</b>
Peptide binding at the GLP-1 receptor <b>R. Mann, N. Nasr, D. Hadden, J. Sinfield, F. Abidi, S. Al-Sabah, R. López de Maturana, J. Treece-Birch, A. Willshaw and D. Donnelly</b>	<b>713–716</b>
Extracellular loops and ligand binding to a subfamily of Family A G-protein-coupled receptors <b>M. Wheatley, J. Simms, S.R. Hawtin, V.J. Wesley, D. Wootten, M. Conner, Z. Lawson, A.C. Conner, A. Baker, Y. Cashmore, R. Kendrick and R.A. Parslow</b>	<b>717–720</b>
Structural characterization of the parathyroid hormone receptor domains determinant for ligand binding <b>D.F. Mierke, L. Mao, M. Pellegrini, A. Piserchio, J. Plati and N. Tsoaia</b>	<b>721–723</b>
Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors <b>I. Langer and P. Robberecht</b>	<b>724–728</b>

Ligand binding and activation of the CGRP receptor <b>A.C. Conner, J. Simms, J. Barwell, M. Wheatley and D.R. Poyner</b>	729-732
Mechanisms underlying agonist efficacy <b>P.G. Strange</b>	733-736
Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges <b>B. Chini and M. Manning</b>	737-741
Phenotypic classification of mutants: a tool for understanding ligand binding and activation of muscarinic acetylcholine receptors <b>E.C. Hulme, M.S. Bee and J.A. Goodwin</b>	742-745
Assessing GPCR activation using protein complementation: a novel technique for HTS <b>R.M. Eglén</b>	746-748
Computational studies of Family A and Family B GPCRs <b>S. Vohra, S.V. Chintapalli, C.J.R. Illingworth, P.J. Reeves, P.M. Mullineaux, H.S.X. Clark, M.K. Dean, G.J.G. Upton and C.A. Reynolds</b>	749-754
	
<b>Selected oral communications</b>	
Unravelling the mechanisms underpinning chemokine receptor activation and blockade by small molecules: a fine line between agonism and antagonism? <b>E. Wise and J.E. Pease</b>	755-759
Neurotensin receptor type 1: <i>Escherichia coli</i> expression, purification, characterization and biophysical study <b>P.J. Harding, H. Attrill, S. Ross, J.R. Koeppel, A.N. Kapanidis and A. Watts</b>	760-763
Monitoring interactions between G-protein-coupled receptors and $\beta$ -arrestins <b>K.D.G. Pflieger, M.B. Dalrymple, J.R. Dromey and K.A. Eidne</b>	764-766
<hr/>	
<b>Cell-Penetrating Peptides</b>	
University of Wolverhampton, Telford, U.K., 9-11 May 2007	
<b>Edited by B. Austen (St. George's, University of London, U.K.), J. Howl (Wolverhampton, U.K.), S. Jones (Wolverhampton, U.K.) and B. Lebleu (Montpellier, France)</b>	
<hr/>	
The many futures for cell-penetrating peptides: how soon is now? <b>J. Howl, I.D. Nicholl and S. Jones</b>	767-769
Applications of cell-penetrating peptides in regulation of gene expression <b>P. Järver, K. Langel, S. El-Andaloussi and Ü. Langel</b>	770-774
Cell-penetrating-peptide-based delivery of oligonucleotides: an overview <b>R. Abes, A.A. Arzumanov, H.M. Moulton, S. Abes, G.D. Ivanova, P.L. Iversen, M.J. Gait and B. Lebleu</b>	775-779
Tumour-homing peptides: tools for targeting, imaging and destruction <b>J. Enbäck and P. Laakkonen</b>	780-783
Arginine-rich peptides and their internalization mechanisms <b>S. Futaki, I. Nakase, A. Tadokoro, T. Takeuchi and A.T. Jones</b>	784-787

Cell-surface proteoglycans as molecular portals for cationic peptide and polymer entry into cells <b>G.M.K. Poon and J. Gariépy</b>	<b>788–793</b>
<i>all-D</i> proline-rich cell-penetrating peptides: a preliminary <i>in vivo</i> internalization study <b>S. Pujals, E. Sabidó, T. Tarragó and E. Giralt</b>	<b>794–796</b>
Bax-inhibiting peptides derived from Ku70 and cell-penetrating pentapeptides <b>J.A. Gomez, V. Gama, T. Yoshida, W. Sun, P. Hayes, K. Leskov, D. Boothman and S. Matsuyama</b>	<b>797–801</b>
Targeting aggressive B-cell lymphomas with cell-penetrating peptides <b>A. Melnick</b>	<b>802–806</b>
Cell-penetrating-peptide-mediated siRNA lung delivery <b>S.A. Moschos, A.E. Williams and M.A. Lindsay</b>	<b>807–810</b>
Protein transduction: identification, characterization and optimization <b>J. Tilstra, K.K. Rehman, T. Hennon, S.E. Plevy, P. Clemens and P.D. Robbins</b>	<b>811–815</b>
Tatp-mediated intracellular delivery of pharmaceutical nanocarriers <b>V.P. Torchilin</b>	<b>816–820</b>
Cell-penetrating peptides in drug development: enabling intracellular targets <b>L. Chen and S.D. Harrison</b>	<b>821–825</b>
<b>Selected oral communications</b>	
Cell-penetrating peptide–morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication <i>in vivo</i> <b>H.M. Moulton, S. Fletcher, B.W. Neuman, G. McClorey, D.A. Stein, S. Abes, S.D. Wilton, M.J. Buchmeier, B. Lebleu and P.L. Iversen</b>	<b>826–828</b>
Generation, application and quantification of clamp–BioShuttle carriers for plasmid delivery into nuclei of prostate cancer cells <b>R. Pipkorn, W. Waldeck, J.W. Jenne, B. Didingler and K. Braun</b>	<b>829–832</b>
Targeting the MHC II presentation pathway in allergy vaccine development <b>C. Rhyner, T. Kündig, C.A. Akdis and R. Crameri</b>	<b>833–834</b>